| 沙库巴曲缬沙坦对不同射血分数心力衰竭患者的疗效及预后 |
| |
| 引用本文： | 黎冉,谢丽娟,焦长青,陆红红,周碧蓉.沙库巴曲缬沙坦对不同射血分数心力衰竭患者的疗效及预后[J].中华全科医学,2021,19(1):10-13. |
| |
| 作者姓名： | 黎冉 谢丽娟 焦长青 陆红红 周碧蓉 |
| |
| 作者单位： | 安徽医科大学第一附属医院心血管内科，安徽 合肥 230032 |
| |
| 基金项目： | 安徽省卫生健康适宜技术推广项目(2018-TG03);安徽省教育厅医学科研课题重点项目(KJ2018A0708);安徽省学术和技术带头人及后备人选学术科研项目(2017H118)。 |
| |
| 摘 要： | 目的 观察沙库巴曲缬沙坦对于不同射血分数慢性心力衰竭(chronic heart failure,CHF)患者的疗效、预后及治疗安全性.方法 选取2019年1-12月于安徽医科大学第一附属医院心内科住院的CHF患者78例,根据射血分数情况分为射血分数减少(HFrEF)组(共40例)和射血分数保留(HFpEF)组(共38...
|
| 关 键 词： | 沙库巴曲缬沙坦 心力衰竭 射血分数 |
| 收稿时间： | 2020-08-25 |
Clinical effect and prognosis of sacubitril-valsartan in treating heart failure patients with different ejection fraction |
| |
| Authors: | LI Ran XIE Li-juan JIAO Chang-qing LU Hong-hong ZHOU Bi-rong |
| |
| Affiliation: | Department of Cardiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230032, China |
| |
| Abstract: | Objective To observe the clinical effect,prognosis and safety of sacubitril-valsartan in treating chronic heart failure(CHF)patients with different ejection fraction.Methods Seventy-eight patients were obtained from the Department of Cardiology of The First Affiliated Hospital of Anhui Medical University from January 2019 to December 2019.The patients were divided into the HFrEF group and HFpEF group on the basis of ejection fraction:40 patients in the HFrEF group and 38 patients in the HFpEF group.All patients were treated with sacubitril-valsartan on the basis of routine heart failure treatment.Brain natriuretic peptide(BNP),renal function,serum potassium,left ventricular ejection fraction(LVEF),left atrial diameter(LAD),left ventricular end diastolic diameter(LVEDD)and New York heart function classification(NYHA)of both groups were compared after 6 months of treatment.Treatment safety was also assessed.The end point event was cardiovascular death or hospitalisation for worsening heart failure.The accumulated end-point event-free survival rate in 6 months between the two groups was compared by the Kaplan-Meier survival curve method.Results After 6 months of treatment,the HFrEF group showed significantly decreased BNP,LAD and LVEDD;significantly increased LVEF and significantly improved NYHA classification(all P<0.05)compared with that before treatment.After 6 months of treatment,the HFpEF group also showed significantly decreased BNP,LAD and LVEDD;significantly increased LVEF and significantly improved NYHA classification(all P<0.05)compared with that before treatment.However,the degree of decrease in the BNP levels and improvement in NYHA class were better in the HFrEF group than that in the HFpEF group.No difference in cumulative event-free survival was found between the HFrEF and HFpEF groups(81.9%vs.85.0%,P=0.694).Safety was good in both groups.Conclusion Sacubitril-valsartan has a certain effect on heart failure with preserved ejection fraction,which shows potential clinical application,but it is slightly less effective on heart failure with reduced ejection fraction.There is no significant difference in prognosis and safety between the two groups. |
| |
| Keywords: | Sacubitril-valsartan Heart failure Ejection fraction |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《中华全科医学》浏览原始摘要信息 |
|
点击此处可从《中华全科医学》下载全文 |
|
